<DOC>
	<DOCNO>NCT00156299</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood patient cancer laboratory may help doctor learn change occur cancer cell . It may also help doctor understand cancer cell respond treatment choline magnesium trisalicylate . PURPOSE : This pilot clinical trial study gene expression cancer cell chemotherapy safety choline magnesium trisalicylate treat patient newly diagnose acute myeloid leukemia .</brief_summary>
	<brief_title>Gene Expression During Chemotherapy Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine temporal change leukemic cell NF-kB activity choline magnesium trisalicylate administer induction chemotherapy patient newly diagnose acute myeloid leukemia . - Determine toxicity regimen patient . Secondary - Determine pattern leukemic cell gene expression patient treat regimen . - Determine NF-kB modulation result enhance apoptosis patient treat regimen . OUTLINE : This open-label , pilot study . Patients receive oral choline magnesium trisalicylate every 8 hour 48 hour dexamethasone every 6 hour 48 hour plus choline magnesium trisalicylate every 8 hour 48 hour induction chemotherapy determine primary physician . Blood collect baseline , 24 hour , 48 hour assess change NF-kB expression , apoptosis , gene expression leukemic cell . PROJECTED ACCRUAL : A total 24 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Choline magnesium trisalicylate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Choline</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute myeloid leukemia Newly diagnose disease Presence cytogenetic abnormality must determine standard cytogenetics without FISH study Leukemic blast count &gt; 5,000/mmÂ³ peripheral blood No acute promyelocytic leukemia ( M3 ) PATIENT CHARACTERISTICS : ECOG performance status 03 Bilirubin &lt; 2.0 time upper limit normal ( ULN ) AST &lt; 3.0 time ULN Creatinine &lt; 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled psychiatric illness , opinion principal investigator , would preclude study compliance No concurrent medical condition would preclude study compliance No allergies investigational drug and/or chemotherapeutic agent No upper low gastrointestinal ( GI ) relate hemorrhage within past 6 month determine endoscopy No clinical diagnosis GI bleed require blood transfusion PRIOR CONCURRENT THERAPY : No prior induction therapy No prior chemotherapy acute leukemia No concurrent medication would preclude study compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
</DOC>